tradmap

BEAM Beam Therapeutics Inc.

$29.45 +0.53%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc. (BEAM) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.0 billion. Shares last traded at $29.45, 23.0% below their 52-week high. Over the past year the stock is up 56.7%. Net profit margin is -54.7%, below the peer median of 5.3%. Revenue grew 120.0% year over year.

Market Cap
$3.0B
Shares Out
103.3M
EPS (TTM)
$-8.53
P/E Ratio
P/S Ratio
19.49
P/B Ratio
2.85
Dividend / Share
Dividend Yield
52-Week High
$38.24
52-Week Low
$17.77
Volume
45,797
Avg Vol (3m)
95,458.825

Performance

1W
-3.32%
1M
+8.77%
3M
-10.30%
6M
+15.44%
YTD
+8.55%
1Y
+56.73%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
53.29
SMA (50)
$29.44
SMA (200)
$28.49
Price vs SMA50
+0.04%
Price vs SMA200
+3.38%
ATR (14)
$1.56

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$156M
Net Income
$-85M
Gross Margin
Operating Margin
-242.3%
Net Margin
-54.7%
Return on Equity
-8.0%
Return on Assets
-6.2%
Current Ratio
14.57
Debt / Equity
0.09
Revenue Growth (YoY)
+120.0%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-2.09 2026-08-04
Q1 2026 $-0.91 2026-05-07
FY 2025 $-0.81 2026-02-24
Q3 2025 $-3.32 2025-11-04
Q2 2026 $-2.21 2026-08-04
Q1 2026 $-1.23 2026-05-07

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

BEAM vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
19.49 / 19.49 med
+0% premium
Net margin vs peers
-54.7% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.